SCHEDULE: Vivo Opportunity Funds Increase Stake in Achieve Life Sciences

Vivo Opportunity Funds collectively report beneficial ownership of 5.3 million shares, representing 5.0% of Achieve Life Sciences' outstanding common stock, including shares issuable upon warrant exercise.

Summary

• Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P., Vivo Opportunity Co-Invest (Cycle 3), L.P., and their general partner Vivo Opportunity, LLC, along with Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC, have filed a Schedule 13G.
• Collectively, these entities report beneficial ownership of 5,305,640 shares of Achieve Life Sciences, Inc. common stock, representing 5.0% of the outstanding shares.
• This total includes 2,652,820 shares held directly and 2,652,820 shares issuable upon the exercise of warrants.
• The filing also details individual holdings and percentages for each reporting entity, ranging from 0.2% to 5.0%.
• The reporting persons certify that these securities were not acquired or held for the purpose of influencing or changing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on ownership stakes and does not provide performance data or strategic insights into the company's operations or future prospects.

Positives

• The reporting entities have a significant collective stake, indicating a substantial investment in Achieve Life Sciences.
• The aggregate beneficial ownership of 5.0% is a notable position, potentially giving the funds a degree of influence or interest in the company's performance.

Negatives

• The filing does not contain financial performance data or operational updates for Achieve Life Sciences, Inc., making it difficult to assess the underlying value of the investment.
• The information is limited to ownership stakes and does not provide insight into the strategic rationale or future intentions of the Vivo Opportunity Funds beyond their current holdings.

Risks

• The warrants held by the reporting persons contain provisions that limit exercise if it would result in the holder exceeding 9.99% of the Issuer's voting securities, capping potential ownership increases through these instruments.
• The filing does not provide specific details on the terms or expiration of the warrants, which could impact their value and the reporting persons' ability to convert them into shares.

Future Outlook

The filing does not contain forward-looking statements or guidance from Achieve Life Sciences, Inc. The future outlook is limited to the reporting persons' current ownership and the restrictions on warrant exercise.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The significant collective ownership by Vivo Opportunity Funds suggests a substantial interest in Achieve Life Sciences, Inc., which operates in the life sciences sector, an area often characterized by long development cycles and significant capital requirements.

Stakeholder Impact

• Shareholders: The increased stake by Vivo Opportunity Funds may be viewed positively by some shareholders as an indication of confidence in the company, while others may be concerned about potential influence on corporate strategy.
• Management: The filing may signal increased scrutiny or potential engagement from a significant investor.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The reporting persons will file amendments to this statement on Schedule 13G for any subsequent changes to their holdings.
• The reporting persons will continue to monitor their investment in Achieve Life Sciences, Inc.

Key Dates

Keywords

Schedule 13G, Achieve Life Sciences, Vivo Opportunity Fund, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment, Securities